scholarly journals Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

2021 ◽  
Vol 384 (8) ◽  
pp. 717-726
Author(s):  
Stephen K. Brannan ◽  
Sharon Sawchak ◽  
Andrew C. Miller ◽  
Jeffrey A. Lieberman ◽  
Steven M. Paul ◽  
...  
2000 ◽  
Vol 42 (3) ◽  
pp. 249-259 ◽  
Author(s):  
Harlan E. Shannon ◽  
Kurt Rasmussen ◽  
Frank P. Bymaster ◽  
John C. Hart ◽  
Steven C. Peters ◽  
...  

2018 ◽  
Vol 33 (2) ◽  
pp. 255-257 ◽  
Author(s):  
Bernard R Bukala ◽  
Michael Browning ◽  
Philip J Cowen ◽  
Catherine J Harmer ◽  
Susannah E Murphy

There has been increasing interest in the antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine. Here we assess, for the first time, whether a transdermal scopolamine patch is sufficient to induce changes in cognition that are consistent with the reported cognitive and antidepressant effects of scopolamine. A scopolamine or placebo patch was administered to healthy volunteers ( n=33) for 17 h in a double-blind, between-subject procedure. There was no clear effect of scopolamine patch on emotional cognition, verbal or working memory, suggesting that the effective dose of scopolamine available through the patch is too low to represent a viable antidepressant mechanism.


Sign in / Sign up

Export Citation Format

Share Document